8 rezultatima
Partecipants
Inclusion criteria:
- Patients with urothelial high risk NMIBC (high grade stage Ta, T1 and/or carcinoma in situ) after intravesical BCG failure;
- adequate bone marrow reserve;
- normal renal function;
- normal liver function;
- Karnofsky performance score of 50 to 100.
Exclusion
Jaundice is the yellow discoloration of skin, sclerae, and other tissues caused by the deposition of bilirubin.
Approximately 60% of term and 80% of preterm babies develop jaundice in the first week of life, and about 10% of breastfed babies are still jaundiced at 1 month. Jaundice is a common cause
PRIMARY OBJECTIVES:
I. This prospective trial will evaluate total response rate, including complete and partial response, in patients with unresectable extremity melanoma (or other skin cancer including but not limited to Merkel cell carcinoma) or soft tissue sarcoma treated with
Back ground: intestinal microbiota have a central role in disease pathogenesis, either in a form of a "permissive" role or as a direct pathogenic cause.
Clostridium difficile colitis; irritable bowel syndrome (IBS) and IBD have all been connected to a disturbance in the equilibrium of intestinal
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence1. Pro-inflammatory cytokines, such as IL-6,
Research Design and Methods
Vaccine field sites and overall study design:
Mirpur. The vaccine studies will be carried out at the field site in Mirpur, in urban Dhaka, where oral cholera, ETEC and rotavirus studies as well as amoebiasis studies are being conducted over the last 15 years . For the
5 PATIENT SELECTION 5.1 Eligibility Criteria
Patients must fulfill all the following criteria to be eligible for admission for the study:
1. Histologically proven central nervous system lymphoma of brain parenchyma with or without leptomeningeal involvement.
2. No evidence of systemic lymphoma.
3.
Background:
A previous clinical trial has been conducted in the Surgery Branch National Cancer Institute (NCI) in which gp100 immunizations have been administered to patients with melanoma in the adjuvant setting. In this prior protocol, the peptide emulsified in Incomplete Freund's Adjuvant was